Axsome Therapeutics

AXSM · Nasdaq · United States

Share price · AXSM

$134.00-81.69 (-37.87%) 3M

close as of 2026-11-18 · 24h delayed · vol 744K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AXSM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+5.9%
  2. 10 Nov 2026+5.2%
  3. 23 Oct 2026-7.1%
  4. 11 Sep 2026+4.6%
  5. 4 May 2026+8.3%
  6. 30 Apr 2026+12.9%
  7. 31 Dec 2025+22.8%

Share of unusual movement by asset

For each asset, the share of AXSM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Dextromethorphan/bupropion (Auvelity)
events and moves
824%
Solriamfetol (Sunosi)
events and moves
103%
Meloxicam/Rizatriptan (Symbravo) (Symbravo)
events and moves
5shown from 8 days
Reboxetine
events and moves
3shown from 8 days
Esreboxetine
events and moves
2shown from 8 days
Balipodect (TAK-063)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—9%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—48%

Assets

(6 total)
6Total Assets
3Approved
2Phase 3 / Filed
1Phase 1–2 / Early
7Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
sigma-1/NMDA · Dopamine/norepinephrine transporterSmall molecule
Major Depressive DisorderAlzheimer's Disease
Alzheimer's Disease Agitation
Approved
5-HT1B/1D receptor · Nonsteroidal Anti-inflammatory DrugSmall molecule
Migraine
Solriamfetol(Sunosi)
Approved
Dopamine/norepinephrine transporterSmall molecule
Major Depressive DisorderNarcolepsyAttention Deficit Hyperactivity Disorder
Phase 3
norepinephrine transporterSmall molecule
Fibromyalgia
Phase 3
norepinephrine transporterSmall molecule
Narcolepsy
Balipodect (TAK-063)No recent activity
Phase 2
Phosphodiesterase 10A (PDE10A)Small molecule
Schizophrenia

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Solriamfetol · SunosiPhase 3Binge-Eating Disorder
Est. primary completion 2026-12 · NCT06413433 · CT.gov ↗
What to watch
Solriamfetol · SunosiPhase 3Excessive Sleepiness, Shift-work Disorder
Est. primary completion 2026-12 · NCT06568367 · CT.gov ↗
What to watch
2027 (3)
December 2027 (3)
Solriamfetol · SunosiPhase 3Binge-Eating Disorder
Est. primary completion 2027-12 · NCT06878976 · CT.gov ↗
What to watch
Est. primary completion 2027-12 · NCT07773883 · CT.gov ↗
What to watch
Est. primary completion 2027-12 · NCT07766655 · CT.gov ↗
What to watch
2028 (5)
March 2028 (1)
EsreboxetinePhase 3Fibromyalgia
Est. primary completion 2028-03 · NCT07398417 · CT.gov ↗
What to watch
May 2028 (1)
EsreboxetinePhase 3Fibromyalgia
Est. primary completion 2028-05 · NCT07637162 · CT.gov ↗
What to watch
June 2028 (2)
Est. primary completion 2028-06-30 · NCT07717879 · CT.gov ↗
What to watch
Est. primary completion 2028-06-30 · NCT07717892 · CT.gov ↗
What to watch
December 2028 (1)
Solriamfetol · SunosiPhase 3Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Est. primary completion 2028-12 · NCT07484217 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 May 2027FDA action dateAXS-12AXS-12 NDA PDUFA target action date
US, FDA · Axsome Therapeutics · Source ↗

Recent

15 July 2026Filing acceptedAXS-12FDA accepts AXS-12 NDA
US, FDA · Axsome Therapeutics · Source ↗
30 April 2026ApprovalDextromethorphan/bupropionFDA approves Auvelity for Alzheimer's disease agitation
US, FDA · Axsome Therapeutics · Source ↗
31 December 2025Priority reviewDextromethorphan/bupropionFDA accepts AXS-05 sNDA with Priority Review
US, FDA · Axsome Therapeutics · Source ↗
25 March 2025Topline resultSolriamfetolFOCUS Phase 3 of solriamfetol in adult ADHD (NCT05972044) met its primary endpoint
Axsome Therapeutics, Inc. · Source ↗
30 December 2024Topline resultDextromethorphan/bupropionACCORD-2 Phase 3 met primary endpoint
Axsome Therapeutics · Source ↗
26 November 2024Topline resultReboxetineENCORE (NCT05113745) Phase 3 met its primary endpoint
Axsome Therapeutics, Inc. · Source ↗
25 March 2024Topline resultReboxetineSYMPHONY (NCT05059223) Phase 3 met its primary endpoint
Axsome Therapeutics, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$260M$51M$314M$13M-$9.5M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$218M$46M$320M$51M-$33M operating cash flowreport ↗
2026-Q1$191M$53M$305M$65M-$21M operating cash flowreport ↗
2025-Q3$171M$40M$325M$47M$1.1M operating cash flowreport ↗
2025-Q2$150M$50M$303M$48M-$32M operating cash flowreport ↗
2025-Q1$121M$45M$301M$59M-$43M operating cash flowreport ↗
2024-Q3$105M$45M$327M$65M-$19M operating cash flowreport ↗
2024-Q2$87M$50M$316M$79M-$30M operating cash flowreport ↗
2024-Q1$75M$37M$331M$68M-$53M operating cash flowreport ↗
2023-Q3$58M$29M$417M$62M-$54M operating cash flowreport ↗
2023-Q2$47M$21M$437M$67M-$55M operating cash flowreport ↗
2023-Q1$95M$18M$247M$11M-$5.8M operating cash flowreport ↗
2022-Q3$17M$15M$228M$45M-$23M operating cash flowreport ↗
2022-Q2$8.8M$16M$73M$41M-$34M operating cash flowreport ↗
2022-Q1—$13M$85M$40M-$33M operating cash flowreport ↗
2021-Q3—$13M$115M$35M-$27M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$639M$183M$323M$46M-$93M operating cash flowreport ↗

Axsome reported 2025 full-year revenue of $638.5M, up 65.5% YoY, with R&D spend of $183.28M, down 2.0% YoY. The company held $322.93M in cash and equivalents and recorded a net loss of $183.17M, or $3.68 per share.

Management said current cash is sufficient to fund operations into cash flow positivity. Regulatory and clinical highlights include a Priority Review sNDA for AXS-05 in Alzheimer's disease agitation with a PDUFA date of April 30, 2026, the acquisition of AXS-17, and an on-track NDA submission for AXS-12 in narcolepsy. Axsome also resolved SUNOSI patent litigation with Alkem Laboratories and plans multiple Phase 3 trial initiations across solriamfetol and AXS-05 in 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$386M$187M$315M$72M-$128M operating cash flowreport ↗
2023-FY$271M$98M$386M$60M-$145M operating cash flowreport ↗
2022-FY$50M$58M$201M$47M-$117M operating cash flowreport ↗
2021-FY—$58M$86M$33M-$108M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 30 sales ($112.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-03Jacobson Mark L. · Chief Operating OfficerOption exercise10,000$12.95$130KForm 4
2026-09-03Jacobson Mark L. · Chief Operating OfficerOpen-market sale10,000$208.65$2.1MForm 4
2026-09-03Jacobson Mark L. · Chief Operating OfficerOption exercise (derivative)10,000——Form 4
2026-08-06TABUTEAU HERRIOT · director, Chief Executive Officer, 10% ownerOption exercise4,660$4.95$23KForm 4
2026-08-06TABUTEAU HERRIOT · director, Chief Executive Officer, 10% ownerOpen-market sale4,660$213.95$997KForm 4
2026-08-06TABUTEAU HERRIOT · director, Chief Executive Officer, 10% ownerOption exercise (derivative)4,660——Form 4
2026-08-05TABUTEAU HERRIOT · director, Chief Executive Officer, 10% ownerOption exercise45,004$4.95$223KForm 4
2026-08-05TABUTEAU HERRIOT · director, Chief Executive Officer, 10% ownerOpen-market sale45,004$212.01$9.5MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 405 reporting institutions held 37.9M shares ($6.1B, 72.0% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.3,912,844$661.3M
2VANGUARD PORTFOLIO MANAGEMENT LLC2,058,170$347.9M
3VANGUARD CAPITAL MANAGEMENT LLC1,937,752$327.5M
4FMR LLC1,566,995$264.9M
5Invesco Ltd.1,297,678$219.3M
6GEODE CAPITAL MANAGEMENT, LLC1,162,981$196.6M
7WELLINGTON MANAGEMENT GROUP LLP1,145,306$193.6M
8Deep Track Capital, LP1,100,000$185.9M
9STATE STREET CORP986,809$166.8M
10Assenagon Asset Management S.A.865,958$146.4M
11NOMURA ASSET MANAGEMENT INTERNATIONAL INC.812,809$137.4M
12ADAGE CAPITAL PARTNERS GP, L.L.C.737,578$124.7M
13ALETHEA CAPITAL MANAGEMENT, LLC649,114$109.7M
14D. E. Shaw & Co., Inc.603,465$102.0M
15BANK OF AMERICA CORP /DE/598,091$101.1M